TG Therapeutics (TGTX) Covered By H.C. Wainwright with $38.0 Target; Inovalon Holdings – Class A (INOV) Shorts Down By 2.43%

March 21, 2018 - By Richard Conner

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics has $33 highest and $18 lowest target. $24.21’s average target is 50.14% above currents $16.125 stock price. TG Therapeutics had 20 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Monday, June 5 by Jefferies. The firm earned “Strong Buy” rating on Wednesday, September 9 by Raymond James. Brean Capital reinitiated the stock with “Buy” rating in Thursday, October 6 report. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by FBR Capital on Wednesday, January 17. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Thursday, June 15 by FBR Capital. The firm has “Buy” rating given on Friday, March 9 by FBR Capital. The firm has “Buy” rating by B. Riley & Co given on Friday, December 1. The rating was maintained by H.C. Wainwright on Monday, December 11 with “Buy”. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Hold” rating given on Wednesday, August 12 by Zacks. Suntrust Robinson initiated the shares of TGTX in report on Friday, May 27 with “Buy” rating.

Inovalon Holdings Inc – Class A (NASDAQ:INOV) had a decrease of 2.43% in short interest. INOV’s SI was 7.38 million shares in March as released by FINRA. Its down 2.43% from 7.57 million shares previously. With 476,600 avg volume, 16 days are for Inovalon Holdings Inc – Class A (NASDAQ:INOV)’s short sellers to cover INOV’s short positions. The SI to Inovalon Holdings Inc – Class A’s float is 12.05%. The stock increased 3.08% or $0.325 during the last trading session, reaching $10.875. About 188,871 shares traded. Inovalon Holdings, Inc. (NASDAQ:INOV) has declined 28.38% since March 21, 2017 and is downtrending. It has underperformed by 45.08% the S&P500.

Since December 29, 2017, it had 0 insider purchases, and 1 insider sale for $272,051 activity. Power Sean A sold $272,051 worth of stock or 32,006 shares.

Analysts await TG Therapeutics, Inc. (NASDAQ:TGTX) to report earnings on May, 4. They expect $-0.46 earnings per share, up 11.54% or $0.06 from last year’s $-0.52 per share. After $-0.46 actual earnings per share reported by TG Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.18 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin??s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

The stock increased 0.78% or $0.125 during the last trading session, reaching $16.125. About 318,352 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 60.54% since March 21, 2017 and is uptrending. It has outperformed by 43.84% the S&P500.

Investors sentiment increased to 2 in 2017 Q3. Its up 0.79, from 1.21 in 2017Q2. It is positive, as 11 investors sold TG Therapeutics, Inc. shares while 22 reduced holdings. 11 funds opened positions while 29 raised stakes. 35.13 million shares or 3.60% more from 33.91 million shares in 2017Q2 were reported. California State Teachers Retirement Sys, a California-based fund reported 77,650 shares. Raymond James And Associates invested 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). California Employees Retirement Sys holds 0% or 106,400 shares. Fmr Limited Liability Company holds 0.01% or 6.45M shares. Credit Suisse Ag holds 0% or 224,066 shares. Metropolitan Life Insur invested in 0% or 30,247 shares. Great West Life Assurance Can owns 10,839 shares. Price T Rowe Associates Md reported 0% stake. Blackrock, a New York-based fund reported 3.30M shares. State Of Wisconsin Investment Board, a Wisconsin-based fund reported 41,000 shares. Columbus Circle reported 1.53 million shares. Voya Investment Management Ltd Llc invested in 0% or 22,521 shares. Hollencrest Secs Limited Liability Corporation owns 12,000 shares. Citadel Advsrs Ltd Llc has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). State Common Retirement Fund reported 102,853 shares.

Inovalon Holdings, Inc., a technology company, provides cloud platforms empowering a data-driven transformation from volume to value models throughout the healthcare industry. The company has market cap of $1.57 billion. The firm through, large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and industry-leading subject matter expertise, enables the assessment and improvement of clinical and quality outcomes, and financial performance across the healthcare ecosystem. It has a 45.69 P/E ratio. It serves health plans and well-known provider organizations, as well as pharmaceutical, medical device, and diagnostics companies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News